Standard
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. / Goldhaber, Samuel Z; Leizorovicz, Alain; Kakkar, Ajay K; Haas, Sylvia K; Merli, Geno; Knabb, Robert M; Weitz, Jeffrey I; ADOPT Trial Investigators ; Torp-Pedersen, Christian Tobias.
In:
New England Journal of Medicine, Vol. 365, No. 23, 08.12.2011, p. 2167-77.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Goldhaber, SZ, Leizorovicz, A, Kakkar, AK, Haas, SK, Merli, G, Knabb, RM, Weitz, JI, ADOPT Trial Investigators
& Torp-Pedersen, CT 2011, '
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients',
New England Journal of Medicine, vol. 365, no. 23, pp. 2167-77.
https://doi.org/10.1056/NEJMoa1110899
APA
Goldhaber, S. Z., Leizorovicz, A., Kakkar, A. K., Haas, S. K., Merli, G., Knabb, R. M., Weitz, J. I., ADOPT Trial Investigators
, & Torp-Pedersen, C. T. (2011).
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
New England Journal of Medicine,
365(23), 2167-77.
https://doi.org/10.1056/NEJMoa1110899
Vancouver
Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM et al.
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
New England Journal of Medicine. 2011 Dec 8;365(23):2167-77.
https://doi.org/10.1056/NEJMoa1110899
Author
Goldhaber, Samuel Z ; Leizorovicz, Alain ; Kakkar, Ajay K ; Haas, Sylvia K ; Merli, Geno ; Knabb, Robert M ; Weitz, Jeffrey I ; ADOPT Trial Investigators ; Torp-Pedersen, Christian Tobias. / Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. In: New England Journal of Medicine. 2011 ; Vol. 365, No. 23. pp. 2167-77.
Bibtex
@article{e899879b771f40dda83ce94029b652cc,
title = "Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients",
abstract = "The efficacy and safety of prolonging prophylaxis for venous thromboembolism in medically ill patients beyond hospital discharge remain uncertain. We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin.",
author = "Goldhaber, {Samuel Z} and Alain Leizorovicz and Kakkar, {Ajay K} and Haas, {Sylvia K} and Geno Merli and Knabb, {Robert M} and Weitz, {Jeffrey I} and Torp-Pedersen, {Christian Tobias} and Torp-Pedersen, {Christian Tobias}",
year = "2011",
month = dec,
day = "8",
doi = "http://dx.doi.org/10.1056/NEJMoa1110899",
language = "English",
volume = "365",
pages = "2167--77",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
number = "23",
}
RIS
TY - JOUR
T1 - Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients
AU - Goldhaber, Samuel Z
AU - Leizorovicz, Alain
AU - Kakkar, Ajay K
AU - Haas, Sylvia K
AU - Merli, Geno
AU - Knabb, Robert M
AU - Weitz, Jeffrey I
AU - ADOPT Trial Investigators
AU - Torp-Pedersen, Christian Tobias
PY - 2011/12/8
Y1 - 2011/12/8
N2 - The efficacy and safety of prolonging prophylaxis for venous thromboembolism in medically ill patients beyond hospital discharge remain uncertain. We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin.
AB - The efficacy and safety of prolonging prophylaxis for venous thromboembolism in medically ill patients beyond hospital discharge remain uncertain. We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin.
U2 - http://dx.doi.org/10.1056/NEJMoa1110899
DO - http://dx.doi.org/10.1056/NEJMoa1110899
M3 - Journal article
VL - 365
SP - 2167
EP - 2177
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 23
ER -